Duloxetine in the treatment of major depressive disorder

Abstract: Since depression impacts all body systems, antidepressant treatments should relieve both the emotional and physical symptoms of depression. Duloxetine demonstrated antidepressant efficacy at a dose of 60 mg qd in two placebo-controlled, randomized, double-blind studies and significantly improved remission rates compared with placebo. Duloxetine-treated patients had significant reduction in severity of the symptoms of depression as assessed by the HAM-D17, anxious symptoms as measured by the HAM-A and quality of life measures compared to placebo. Duloxetine also improved somatic symptoms, particularly painful symptoms which may have contributed to significantly improved remission rates compared to placebo. Approximately 10% of the 1139 patients with major depressive disorder in placebo-controlled trials discontinued treatment due to an adverse event, compared to 4% of the 777 patients receiving placebo. In addition to nausea (1.4% incidence), which was the most common reason for discontinuation, dizziness, somnolence, and fatigue were the most common AEs reported as reasons for discontinuation and all were considered drug-related. Duloxetine treatment lacks effects on ECG, increases heart rate, and has little effect on blood pressure or weight.

Keywords: duloxetine, depression, antidepressant, SNRI, quality of life, pain.

Introduction

Clinical presentation of major depressive disorder (MDD)

Depression is associated with both significant functional impairment with work loss, impaired quality of life, and increased use of health care (Wells et al 1989; Hays et al 1995; Bosc 2000; Herrman et al 2002; Simon et al 2002;). Depression is a common, generally chronic, and debilitating psychiatric condition. It is increasingly recognized that depression affects the entire body including painful physical symptoms that may be part of a broader cluster of symptoms that constitute major depressive disorder (Detke et al 2002a, b), not merely emotional symptoms (mood and anxiety). Physical symptoms, including sleep disruption, fatigue, pain and discomfort, and appetite disturbance, are present in up to 80% of depressed patients (Gerber et al 1992). Physical symptoms occur in nearly all body systems and are often the presenting features in the non-psychiatric setting. Jackson et al (2001) found that five or more physical symptoms are a significant predictor of MDD in medical outpatients, with an odds ratio of 4.0. Furthermore, as evidence of their importance, physical symptoms, such as back pain and chest pain, predict greater severity of depression (Gerber et al 1992). Painful physical symptoms are highly prevalent among patients with depression (Simon and Von Korff 1991; Kroenke and Price 1993; Von Korff and Simon 1996; Gureje et al 1997; Gureje et al 1998; Simon et al 1999).

The DSM-IV (APA 1994) defines “major depressive episode” by a cluster of symptoms, including somatic symptoms, representing a change from previous functioning and which must be present for at least 2 weeks. This cluster includes either 1) depressed
mood or 2) loss of interest or pleasure, and five of nine depressive symptoms – depressed mood; anhedonia; appetite or weight change; sleep difficulties; psychomotor agitation or retardation; fatigue or decreased energy; concentration difficulties; feelings of worthlessness or guilt; and recurrent thoughts of death or suicide. Increasing awareness of the association between depression and physical symptoms is reflected in the DSM-IV Text Revision (APA 2000), which describes associated features of major depressive episodes including “complaints of pain (eg, headaches or joint, abdominal, or other pains).”

The prospective naturalistic trial investigating response to SSRI therapy in primary care (the ARTIST study) (Corey-Lisle et al 2004) indicated that most patients continue to have symptoms and impaired role functioning despite treatment (Klerman and Weissman 1992; Cronkite 1998; Corey-Lisle et al 2004). In that study, of the 601 patients randomized to treatment with 6 months of continuous therapy of therapeutic dose of paroxetine, fluoxetine, or sertraline, 46% failed to meet the response criteria of a 50% reduction in their System Checklist (SCL-20) score. In addition, physical symptoms, especially painful symptoms, improved less than emotional symptoms. Unfortunately, in clinical practice, many patients receive inadequate dose strength or treatment duration (Keller et al 1986; Hirschfeld et al 1997), further reducing the effectiveness of treatment. Patients who achieve only partial response to treatment of a depressive episode (partial remission) are more likely to have subsequent episodes.

Many patients who fully recover from a depressive episode eventually relapse, and each subsequent relapse may heighten the risk of a chronic, non-remitting course (Belsher and Costello 1988). The number of prior episodes predicts the likelihood of having subsequent episodes. It has been found that at least 60% of patients have a second episode after their initial episode; after two episodes patients have a 70% chance of having a third episode; and after three episodes, patients have a 90% chance of having a fourth episode (Cohen et al 2004). In a 16-year follow-up of depressed inpatients, 50% showed either a chronic course or a series of relapses leading to a chronic course. As a consequence, the recommended duration of treatment and maintenance has been extended proportionately with the number and chronicity of prior depressive episodes (Kupfer et al 1992).

Other aspects associated with poorer outcome and/or disease persistence include dysthmic disorder, marked severity of the initial episode, and the presence of some chronic general medical conditions (eg, diabetes) (Swindle et al 1998), physical symptoms, and pain. In a study of patients given selective serotonin reuptake inhibitor (SSRI) therapy, physical symptoms were less likely to improve than emotional symptoms, well-being, and work/social function (Greco et al 2004). Increased prevalence rates of depression are found among patients with neurologic (23%) and cardiovascular disease (20%–27%), cancer (25%–42%), diabetes (8.5%–27.3%), and HIV (5.6%–12.2%) (Sutor et al 1998). The presence of major diagnosed medical conditions is a risk factor for a chronic course of depression over 4 years from the initiation of treatment (Swindle et al 1998).

Simon et al (1999) performed an analysis of 1146 subjects with major depression from a WHO screening survey of 25,916 primary care patients in 14 countries. Approximately 50% of those with major depression also reported at least three unexplained physical symptoms. In addition, the number of unexplained physical symptoms was more than three times higher in those with major depression (4.4 ± 4.2) than in those without major depression (1.2 ± 1.9).

Etiology of MDD

Because depression impacts all body systems (Kroenke and Price 1993; Posse and Hallstrom 1998), it is no surprise that investigations attempting to determine the effects of depression on hormones, neurotransmission, brain imaging, sleep architecture, immune function, and so on, have tended to identify differences between depressed patients and normal subjects. However, many of these investigations have not been replicated, or show significant overlap between depressed and non-depressed groups leading to subsequent investigations of subgroups. Such investigations are further complicated by the temporal adaptation that occurs in many biological systems, resulting in differing effects after acute and chronic stress (Goldstein and Potter 2004).

Numerous biochemical mediators have been identified as potential factors related to the development of depression (Goldstein and Potter 2004). Among the best characterized neurotransmitters involved in depression are serotonin (5-HT) and norepinephrine (NE) (Tran et al 2003). Enhancing both 5-HT and NE neurotransmission simultaneously may provide greater efficacy and faster onset of action than enhancing either mechanism alone (Danish University Antidepressant Group 1986, 1990; Nelson et al 1991; Tran et al 2003). Descending 5-HT and NE pathways normally help to suppress pain inputs even when they cause minor discomfort. However, when these neurotransmitter systems malfunction, deficient inhibition from the descending pathways may allow routine sensory input to be interpreted as...
painful physical symptoms. Increasing neurotransmission of both 5-HT and NE may offer greater antidepressant efficacy when compared with potentiation of a single neurotransmitter (Nelson 1998), and may be of clinical utility in the alleviation of painful physical symptoms associated with depression.

Epidemiology and relevant risk factors of MDD

Lifetime prevalence estimates for depression vary across studies, perhaps as a result of differences among instruments and survey methods used to identify the disorder. It is estimated that the lifetime risk for MDD ranges from 10% to 25% for women and from 5% to 12% for men.

The National Comorbidity Survey Replication (NCS-R), conducted with a nationally representative United States sample between 2001 and 2002, supported earlier findings from its predecessor, the National Comorbidity Study (Kessler et al 1994, 1996, 1997). It confirmed that MDD is the single most prevalent psychiatric disorder (Kessler et al 2003). Lifetime prevalence was 16.2%, with 6.6% of the population experiencing an episode in a 12-month period. Lifetime prevalence was greater among women than men and greater among Caucasians than non-Hispanic African-Americans. In addition, lifetime depression was more common among homemakers (12 month only), the previously married (lifetime only), those with less than 12 years of education, and those living in or near poverty. Age of onset tended to rise rapidly from the late teens, with the suggestion that onset rates were earlier for more recent birth cohorts.

Lifetime MDD was comorbid with another psychiatric disorder in nearly 75% of respondents. The most common lifetime comorbid conditions were: anxiety (59%), impulse control disorder (30%), and substance use disorder (24%). MDD was associated with role impairment for nearly all respondents (96.9%) with 12-month MDD. Impairment tended to be most severe in the social role domain (43.4% severe or very severe) and least in the work role domain (28.1% severe or very severe). Despite work being the least impaired domain, respondents with 12-month MDD reported a mean of 35.2 days in the past year in which they were totally unable to work or perform usual activities. Regardless of prevalence estimates, most researchers agree that major depression is under-diagnosed and under-treated (Hirschfeld et al 1997).

Approaches to MDD treatment

According to published practice guidelines, the three primary treatment modalities for major depression are pharmacotherapy, psychotherapy, and their combination (Schulberg et al 1999; APA 2000). Selection of an initial treatment for acute depression is based on several factors including severity of symptoms, physiological and psychiatric comorbidities, subtype of depression, and patient preference. Both pharmacotherapy and psychotherapy are also recommended for continuation treatment (ie, 16–20 weeks following remission) and maintenance treatment to prevent further recurrences of depressive episodes (APA 2000). A recent meta-analysis of randomized, controlled, double-blind clinical trials for MDD found that antidepressants and psychotherapy were both more effective than control conditions (Casacalenda et al 2002). The literature is inconsistent about whether pharmacotherapy and psychotherapy in combination are superior to either treatment modality alone (see Table 1).

Numerous clinical trials have assessed the efficacy of antidepressants, generally indicating that antidepressant treatment of major depression is superior to placebo treatment (Dunbar et al 1993; Ellingrod and Perry 1995; Ballenger 1996; Croft et al 1999; Feighner and Overo 1999; Gorman 1999). The majority of studies that compare multiple antidepressants including SSRIs and tricyclic antidepressants (TCAs) show no significant efficacy differences between them (Holliday and Plosker 1993; Bennie et al 1995; Patris et al 1996; Sechter et al 1999; Stahl 2000; Kroenke et al 2001), but with very high sample size or with meta-analysis using data from multiple studies, TCAs and dual reuptake inhibitors show greater efficacy than SSRIs (Thase 2002). The core difference between the TCAs and SSRIs lies in safety profiles and tolerability. SSRIs lack the potentially serious side-effects of TCAs such as orthostatic hypotension, anticholinergic effects, and cardiac arrhythmia (Peretti et al 2000). SSRIs are also non-toxic in overdose (Mason et al 2000; Peretti et al 2000), their titration tends to be much simpler, and patient dropout rates are lower (Mulrow et al 2000). Dual reuptake inhibitors, such as duloxetine, can maintain the safety and tolerability advantages of the SSRIs.

In the past, clinicians strived for patients to “feel better” (achieve antidepressant “response”); however, the goal has shifted to getting patients “well” or “virtually symptom free” (“remission”) because patients who experience only partial response to treatment of a depressive episode have a greater likelihood of developing subsequent episodes and of continuing to experience only partial recovery between episodes. Remission is ordinarily measured in clinical trials by achievement of a Hamilton Depression Rating Scale (HAM-D) score of ≤7 (Keller 2003).
Duloxetine

Duloxetine, (+)-S-N-methyl-γ-(1-naphthoxy)-2-thiope-
nepropylamine hydrochloride, is a potent inhibitor of both
5-HT and NE reuptake, possesses comparable affinities in
binding to NE and 5-HT transport sites, and has no signifi-
cant affinity for cholinergic, histaminergic, dopaminergic,
opioid, glutamate, GABA, cholinergic and adrenergic receptors in
vitro (Bymaster et al 2001) and does not inhibit monoamine
oxidase. Duloxetine undergoes extensive metabolism, but the
major circulating metabolites have not been shown to con-
tribute signifi cantly to its pharmacologic activity. Preclinical
studies have shown that duloxetine is a potent inhibitor of
neuronal 5-HT and NE reuptake and a less potent inhibitor
of dopamine reuptake.

Although the exact mechanisms of the antidepressant
and central pain inhibitory action of duloxetine in humans
are unknown, the antidepressant and pain inhibitory ac-
tions are believed to be related to its potentiation of 5-HT
and NE activity in the central nervous system (CNS)
(see Pharmacokinetics).

Pharmacokinetics and metabolism

Early duloxetine development was performed using a different
formulation and lower dosage (Berk et al 1997). After failing
to differentiate from placebo in depression Phase II/III trials,
duloxetine was further evaluated and the present formulation
and higher dosages were studied, beginning with new Phase I
studies (Table 2). The absorption, distribution, metabolism,
and elimination of duloxetine are presented in Table 3 (Lantz
et al 2003; Skinner et al 2003, 2004; Eli Lilly and Co 2004;

Efficacy

Duloxetine trials

The efficacy of duloxetine for the acute treatment of
major depressive disorder (MDD) was established in eight
double-blind, randomized, placebo-controlled studies in
adult outpatients who met DSM-IV (APA 1994) criteria
for major depression (see Table 3 for study details). In the
placebo-controlled MDD efficacy trials duloxetine was con-
sistently significantly more effective than placebo at doses
≥60 mg/day.

Studies 1 and 2 were designed to test proof of concept in
two underpowered trials in which one trial (Goldstein et al
2002) showed superiority of duloxetine over placebo. Both
of these studies used markedly under-powered fluoxetine
comparator treatment arms.

Studies 3 and 4 investigated a low and intermediate
dose of duloxetine. In Study 3 paroxetine treatment was
superior to placebo treatment, but duloxetine was not. In
Study 4 (Goldstein et al 2004b), duloxetine treatment at
both dosages was superior to placebo treatment, whereas
paroxetine was not. Although the duloxetine vs parox-
etine comparison was not intended in these trials, Study 4
showed duloxetine at 40 mg bid was superior to paroxetine
20 mg which performed poorly in this trial. If these trials

Table 1: Treatments for major depressive disorder

<table>
<thead>
<tr>
<th>Psychotherapy</th>
<th>Pharmacotherapy</th>
<th>Other therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive-Behavioral (CBT)</td>
<td>SSRIs</td>
<td>Exercise (Pennisin et al 2002)</td>
</tr>
<tr>
<td>Interpersonal psychotherapy (IPT)</td>
<td>Tricyclics</td>
<td>Electro-convulsive therapy (ECT) (Weiner and Coffey 1993)</td>
</tr>
<tr>
<td></td>
<td>SNRI</td>
<td>Acupuncture</td>
</tr>
<tr>
<td></td>
<td>DNRI</td>
<td>Vagus nerve stimulation (VNS) - electrical stimulation of the left</td>
</tr>
<tr>
<td></td>
<td>Non-traditional</td>
<td>vagus nerve in the neck via anterior chest wall-implanted</td>
</tr>
<tr>
<td></td>
<td></td>
<td>stimulator</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Psychosurgery - surgical intervention to sever nerve fibers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>in the brain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transcranial magnetic stimulation (r-TMS) - stimulation of local</td>
</tr>
<tr>
<td></td>
<td></td>
<td>electrical currents in the brain via a strong magnetic field</td>
</tr>
<tr>
<td></td>
<td></td>
<td>created by a stimulating coil</td>
</tr>
</tbody>
</table>

Abbreviations: DNRI, dopamine-norepinephrine reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
### Table 2: Results of Phase I Studies of Duloxetine

#### Pharmacokinetics

| Metabolism | Via CYP2D6 and CYP1A2  
(Lantz et al 2003; Skinner et al 2003)  
Moderate inhibitor of CYP2D6 and CYP1A2  
Inhibitor of in vitro CYP2C9 enzyme activity  
Not inhibitor or inducer of CYP3A activity  
Not inhibitor of CYP2C19 activity  
Extensively metabolized to numerous metabolites.  
Two major metabolites found in plasma: glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5-hydroxy,6-methoxy duloxetine  
Major circulating metabolites have not been shown to contribute significant pharmacologic activity. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Half-life</strong></td>
<td>Approximately 12 hours range (8–17 hours)</td>
</tr>
</tbody>
</table>
| **Absorption** | Orally administered and well absorbed  
Median 2-hour lag until absorption begins (T<sub>lag</sub>)  
Maximal plasma concentration (C<sub>max</sub>) occurring 6 hours post dose  
Food does not affect C<sub>max</sub>; but delays time to peak concentration from 6 to 10 hours and marginally decreases the extent of absorption by about 10%.  
3-hour delay in absorption and a one-third increase in apparent clearance of duloxetine after an evening dose compared with a morning dose  
Dose proportional over the therapeutic range |
| **Distribution** | Average volume of distribution (V<sub>d</sub>) is 1640 L  
>90% bound to serum proteins, primarily to albumin and α<sub>1</sub>-acid glycoprotein  
Plasma protein binding is not affected by renal or hepatic impairment |
| **Excretion** | Major metabolites found in plasma - glucuronide conjugate of 4-hydroxy duloxetine, and the sulfate conjugate of 5-hydroxy,6-methoxy duloxetine.  
<1% of unchanged duloxetine present in urine; about 70% of dose recovered in urine as metabolites; approximately 20% recovered in feces  
About 70% of the duloxetine dose appears in the urine as metabolites; about 20% is excreted in the feces |
| **Steady state** | Typically achieved after 3 days of dosing |

#### Special Populations

| **Age** (Skinner et al 2004) | No difference in C<sub>max</sub> between healthy elderly females (65–77 years) and healthy middle-age females (32–50 years), but AUC 25% higher and half-life of about 4 hours longer in elderly females.  
Population pharmacokinetic analyses suggest that the typical values for clearance decrease by approximately 1% for each year of age between 25 and 75 years of age  
Age as a predictive factor only accounts for a small percentage of between-patient variability  
Dosage adjustment based on the age of the patient is not necessary |
| **Pediatrics** | Safety and efficacy in pediatric patients have not been established |
| **Gender** | Half-life is similar in men and women  
Adverse events seen in men and women were generally similar except for effects on sexual function  
Dosage adjustment based on gender is not necessary |

(continued)
Goldstein

Race

No specific pharmacokinetic study was conducted to investigate the effects of race on duloxetine pharmacokinetics. However, race was included in the population pharmacokinetic analysis of duloxetine. No significant differences were found between African American and non-African American patients. Pregnancy Category C

Pregnancy

Neonates exposed to SSRIs or SNRIs, late in the third trimester, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Duloxetine should not be administered to patients with any hepatic insufficiency. Patients with clinically evident hepatic insufficiency have decreased Cymbalta metabolism and elimination. Markedly increased AUC and T 1/2 after a single 20 mg dose in 6 cirrhotic patients (Child-Pugh Class B), mean plasma clearance was about 15% that of age- and gender-matched healthy subjects, with a 5-fold increase in mean exposure (AUC). Although C max was similar to normals in the cirrhotic patients, the half-life was about 3 times longer.

Liver impairment

(Duli et al 2005) Patients with clinically evident hepatic insufficiency have decreased Cymbalta metabolism and elimination. Markedly increased AUC and T 1/2 after a single 20 mg dose in 6 cirrhotic patients (Child-Pugh Class B), mean plasma clearance was about 15% that of age- and gender-matched healthy subjects, with a 5-fold increase in mean exposure (AUC). Although C max was similar to normals in the cirrhotic patients, the half-life was about 3 times longer.

Renal impairment

In patients with end-stage renal disease (ESRD) or severe renal impairment (creatinine clearance < 30 mL/min) duloxetine is not recommended. Duloxetine C max and AUC values were approximately 100% greater in patients with ESRD receiving chronic intermittent hemodialysis, but elimination half-life was similar to normal controls. Clinical pharmacology studies have not been conducted in patients with a moderate degree of renal dysfunction, but population PK analyses suggest that mild renal dysfunction estimated CrCl 30–80 mL/min has no significant effect on duloxetine apparent clearance.

Other

Sustained hypertension

In clinical trials, duloxetine treatment was associated with mean increases in blood pressure, averaging 2 mmHg systolic and 0.5 mmHg diastolic and an increase in the incidence of at least one measurement of systolic blood pressure over 140 mmHg compared with placebo.

QTc prolongation

None. In the placebo-controlled studies, duloxetine 60 mg bid-treated patients experienced a statistically significant decrease in Fridericia’s corrected QTc interval QTcF compared with placebo-treated patients -2.86 msec vs 0.57 msec, respectively; p = 0.033. However, when pooled across all doses, neither the mean change in QTcF interval nor incidence of QTcF prolongations among duloxetine-treated patients differed significantly from the placebo group (Thase et al 2005).

Laboratory changes

Small mean increases from baseline to endpoint in ALT, AST, CPK, and alkaline phosphatase were observed in both groups (duloxetine -0.03 vs placebo -0.05) (Eli Lilly and Co 2004).

Glycemic control

In placebo-controlled studies, mean frequency of significant hypoglycemic episodes was significantly higher for the duloxetine treatment group compared with the placebo group (0.06 episodes/week vs 0.05 episodes/week, respectively)

In placebo-controlled studies, the mean increase in fasting glucose for placebo-treated patients was 0.35 mmol/L (6.3 mg/dL), and for duloxetine-treated patients was 0.98 mmol/L (18 mg/dL); p = 0.022. A non-significant difference was observed between duloxetine and placebo, in hemoglobin A1c HbA1c values observed in both groups (duloxetine -0.03 vs placebo -0.05) (Eli Lilly and Co 2004).

Smoking status

Bioavailability (AUC) is about one-third lower in smokers than in non-smokers. Dosage adjustment is not recommended.

Table 2 Continued

Special populations

<table>
<thead>
<tr>
<th>Race</th>
<th>No specific pharmacokinetic study was conducted to investigate the effects of race</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy</td>
<td>Pregnancy Category C</td>
</tr>
<tr>
<td>Neonates exposed to</td>
<td>Neonates exposed to SSRIs or SNRIs, late in the third trimester, have developed</td>
</tr>
<tr>
<td>SSRIs or SNRIs,</td>
<td>complications requiring prolonged hospitalization, respiratory support, and tube</td>
</tr>
<tr>
<td>late in the third</td>
<td>feeding.</td>
</tr>
<tr>
<td>trimester, have</td>
<td>Duloxetine should not be administered to patients with any hepatic insufficiency</td>
</tr>
<tr>
<td>developed</td>
<td>Patients with clinically evident hepatic insufficiency have decreased Cymbalta</td>
</tr>
<tr>
<td>complications</td>
<td>metabolism and elimination. Markedly increased AUC and T 1/2 after a single 20</td>
</tr>
<tr>
<td>requiring</td>
<td>mg dose in 6 cirrhotic patients (Child-Pugh Class B), mean plasma clearance was</td>
</tr>
<tr>
<td>prolonged</td>
<td>about 15% that of age- and gender-matched healthy subjects, with a 5-fold increase</td>
</tr>
<tr>
<td>hospitalization,</td>
<td>in mean exposure (AUC). Although C max was similar to normals in the cirrhotic</td>
</tr>
<tr>
<td>respiratory support,</td>
<td>patients, the half-life was about 3 times longer.</td>
</tr>
<tr>
<td>and tube feeding</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>Duloxetine should not be administered to patients with any hepatic insufficiency</td>
</tr>
<tr>
<td>impairment (Suri et</td>
<td>Patients with clinically evident hepatic insufficiency have decreased Cymbalta</td>
</tr>
<tr>
<td>al 2005)</td>
<td>metabolism and elimination. Markedly increased AUC and T 1/2 after a single 20</td>
</tr>
<tr>
<td>Renal</td>
<td>mg dose in 6 cirrhotic patients (Child-Pugh Class B), mean plasma clearance was</td>
</tr>
<tr>
<td>impairment</td>
<td>about 15% that of age- and gender-matched healthy subjects, with a 5-fold increase</td>
</tr>
<tr>
<td></td>
<td>in mean exposure (AUC). Although C max was similar to normals in the cirrhotic</td>
</tr>
<tr>
<td></td>
<td>patients, the half-life was about 3 times longer.</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Sustained hypertension</td>
<td>In clinical trials, duloxetine treatment was associated with mean increases in</td>
</tr>
<tr>
<td></td>
<td>blood pressure, averaging 2 mmHg systolic and 0.5 mmHg diastolic and an increase</td>
</tr>
<tr>
<td></td>
<td>in the incidence of at least one measurement of systolic blood pressure over 140</td>
</tr>
<tr>
<td></td>
<td>mmHg compared with placebo.</td>
</tr>
<tr>
<td>QTc prolongation</td>
<td>None. In the placebo-controlled studies, duloxetine 60 mg bid-treated patients</td>
</tr>
<tr>
<td></td>
<td>experienced a statistically significant decrease in Fridericia’s corrected QTc</td>
</tr>
<tr>
<td></td>
<td>interval QTcF compared with placebo-treated patients -2.86 msec vs 0.57 msec,</td>
</tr>
<tr>
<td></td>
<td>respectively; p = 0.033. However, when pooled across all doses, neither the mean</td>
</tr>
<tr>
<td></td>
<td>change in QTcF interval nor incidence of QTcF prolongations among duloxetine-</td>
</tr>
<tr>
<td></td>
<td>treated patients differed significantly from the placebo group (Thase et al 2005)</td>
</tr>
<tr>
<td>Laboratory changes</td>
<td>Small mean increases from baseline to endpoint in ALT, AST, CPK, and alkaline</td>
</tr>
<tr>
<td>Glycemic control</td>
<td>phosphatase were observed in both groups (duloxetine -0.03 vs placebo -0.05)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Bioavailability (AUC) is about one-third lower in smokers than in non-smokers.</td>
</tr>
</tbody>
</table>

Abbreviations: SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
**Table 3** Duloxetine placebo-controlled major depressive disorder efficacy trials (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Purpose</th>
<th>Study design</th>
<th>Treatments (n)</th>
<th>Treatment duration</th>
<th>Results of primary efficacy measure (mixed model repeated measures analysis)</th>
<th>Probability of remission</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (Goldstein et al 2002)</td>
<td>Proof of Concept</td>
<td>Phase II, parallel, double-blind, placebo- and fluoxetine controlled, randomized, forced titration</td>
<td>Forced titration to duloxetine 60 mg bid (70) Fluoxetine 20 mg qd (33) Placebo (70)</td>
<td>8 weeks</td>
<td>Mean change HAM-D17 total score: Duloxetine –9.7* vs placebo –6.6</td>
<td>Duloxetine: 56%* Fluoxetine: 30% Placebo: 32%</td>
</tr>
<tr>
<td>2 (Mallinckrodt et al 2004)</td>
<td>Proof of Concept</td>
<td>Phase II, parallel, double-blind, placebo- and fluoxetine- controlled, randomized, forced titration</td>
<td>Forced titration to duloxetine 60 mg bid (82) Fluoxetine 20 mg qd (37) Placebo (75)</td>
<td>8 weeks</td>
<td>Mean change HAM-D17 total score: Duloxetine –8.0 vs placebo –7.1</td>
<td>Duloxetine: 53% Fluoxetine: 38% Placebo: 38%</td>
</tr>
<tr>
<td>3 (Mallinckrodt et al 2004)</td>
<td>Dose Finding</td>
<td>Phase III, parallel, double-blind, placebo-and paroxetine- controlled, randomized, fixed dose</td>
<td>Duloxetine 20 mg bid (91) Fluoxetine 20 mg bid (89) Placebo (90)</td>
<td>8 weeks</td>
<td>Mean change HAM-D17 total score: Duloxetine (40 mg/d) –6.2 vs placebo –5.0</td>
<td>Duloxetine (40 mg/d): 27% Fluoxetine (80 mg/d): 35% Placebo: 22%</td>
</tr>
<tr>
<td>4 (Mallinckrodt et al 2004)</td>
<td>Dose Finding</td>
<td>Phase III, parallel, double-blind, placebo-and paroxetine- controlled, randomized, fixed dose</td>
<td>Duloxetine 20 mg bid (86) Fluoxetine 20 mg bid (87) Placebo (89)</td>
<td>8 weeks</td>
<td>Mean change HAM-D17 total score: Duloxetine (80 mg/d) –8.6*** vs placebo –5.0</td>
<td>Duloxetine (80 mg/d): 36% Fluoxetine (80 mg/d): 57%*** Paroxetine: 34% Placebo: 25%</td>
</tr>
</tbody>
</table>

(continued)
Table 3 Duloxetine placebo-controlled major depressive disorder efficacy (trials concluded)

<table>
<thead>
<tr>
<th>Study 5 (Detke et al 2004)</th>
<th>Study 6 (Goldstein et al 2004b)</th>
<th>Study 7 (Detke et al 2002a)</th>
<th>Study 8 (Detke et al 2002b)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>Dose Finding</td>
<td>Pivotal Trial</td>
<td>Pivotal Trial</td>
</tr>
<tr>
<td><strong>Study design</strong></td>
<td>Phase III, parallel, double-blind, placebo-and paroxetine- controlled, randomized, fixed dose</td>
<td>Phase III, parallel, double-blind, placebo-controlled, fixed-dose, randomized</td>
<td>Phase III, parallel, double-blind, placebo-controlled, fixed-dose, randomized</td>
</tr>
<tr>
<td><strong>Treatments (n)</strong></td>
<td>Duloxetine 40 mg bid (95)</td>
<td>Duloxetine 40 mg bid (93)</td>
<td>Duloxetine 60 mg qd (123)</td>
</tr>
<tr>
<td></td>
<td>Duloxetine 60 mg bid (93)</td>
<td>Duloxetine 60 mg bid (103)</td>
<td>Placebo (122)</td>
</tr>
<tr>
<td></td>
<td>Paroxetine 20 mg qd (86)</td>
<td>Paroxetine 20 mg qd (97)</td>
<td>Placebo (122)</td>
</tr>
<tr>
<td></td>
<td>Placebo (93)</td>
<td>Placebo (99)</td>
<td>Placebo (99)</td>
</tr>
<tr>
<td><strong>Treatment Duration</strong></td>
<td>8 weeks of acute treatment, followed by 26-week continuation for responders</td>
<td>8 weeks of acute treatment, followed by 26-week continuation for responders</td>
<td>9 weeks</td>
</tr>
<tr>
<td><strong>Results of</strong></td>
<td>Mean change HAM-D$_{17}$, total score:</td>
<td>Mean change HAM-D$_{17}$, total score:</td>
<td>HAM-D$_{17}$ total score:</td>
</tr>
<tr>
<td><strong>Primary efficacy</strong></td>
<td>Duloxetine (80 mg/d): –11.0$^{**}$</td>
<td>Duloxetine (80 mg/d): –12.1$^*$</td>
<td>Duloxetine: –10.9$^{**}$</td>
</tr>
<tr>
<td><strong>measure (mixed model repeated measures analysis)</strong></td>
<td>Duloxetine (120 mg/d): –12.1$^{**}$</td>
<td>Duloxetine (120 mg/d): –12.4$^*$</td>
<td>Placebo: –6.1</td>
</tr>
<tr>
<td></td>
<td>Paroxetine: –11.7$^{**}$</td>
<td>Paroxetine: –11.9</td>
<td>Placebo: –10.8</td>
</tr>
<tr>
<td><strong>Probability of Remission:</strong></td>
<td>Remission:</td>
<td>Remission:</td>
<td>Response:</td>
</tr>
<tr>
<td><strong>Response or Remission</strong></td>
<td>Duloxetine (80 mg/d): 51$^{%}$</td>
<td>Duloxetine (80 mg/d): 49$^{%}$</td>
<td>Duloxetine: 62$^{**}$</td>
</tr>
<tr>
<td></td>
<td>Duloxetine (120 mg/d): 58$^{%}$</td>
<td>Duloxetine (120 mg/d): 45%</td>
<td>Placebo: 29%</td>
</tr>
<tr>
<td></td>
<td>Paroxetine: 47$^{%}$</td>
<td>Paroxetine: 48%</td>
<td>Remission:</td>
</tr>
<tr>
<td></td>
<td>Placebo: 30%</td>
<td>Placebo: 34%</td>
<td>Duloxetine: 44$^{***}$</td>
</tr>
<tr>
<td></td>
<td>Placebo: 16%</td>
<td>Placebo: 29%</td>
<td>Placebo: 16%</td>
</tr>
</tbody>
</table>

*p ≤ 0.05 vs placebo; **p ≤ 0.005 vs placebo; ***p ≤ 0.001 vs placebo; †p ≤ 0.05 vs duloxetine 40 mg/d; ‡p ≤ 0.05 vs paroxetine.
were pooled, the results would likely show that duloxetine 40 mg bid was superior to placebo at the higher dose and that paroxetine was not. Duloxetine would have been numerically superior, but not statistically significantly different from paroxetine. Studies 5 and 6 investigated an intermediate dose and high dose of duloxetine. The intermediate dose of 40 mg bid was the same as that used in Studies 3 and 4 so that there would be a common reference dose for inferring the relationship of the low dose in Studies 3 and 4 to the high dose in Studies 5 and 6. Study 5 showed that both duloxetine doses and the paroxetine dose were superior to placebo, but duloxetine and paroxetine treatments did not differ statistically. Study 6 showed that both doses of duloxetine were superior to placebo, but paroxetine was not. If these studies had been pooled, both doses of duloxetine would have been significantly superior to placebo, but paroxetine treatment would not. Duloxetine would have been numerically superior, but not statistically significantly different from paroxetine.

Studies 7 and 8 (Detke et al 2002a, b) were intended to evaluate whether a single 60 mg dose of duloxetine daily would be sufficient for treatment. Both studies confirmed the efficacy of 60 mg qd. It is valuable to note that the sample sizes were higher in these studies, compared with the prior studies, so that a smaller effect could be identified, possibly accounting for the highly significant differences from placebo treatment.

Other duloxetine MDD trials
Additional trials (Table 4) were performed to meet regulatory requirements or expand an understanding of the usefulness of duloxetine.

Study 9 was an open label safety trial used to increase the number of patients treated for 1-year in the regulatory package. The long-term efficacy of duloxetine in elderly patients was demonstrated in the subset of patients aged 65 years and older (n = 101) who participated in this study (Eli Lilly and Co 2004). A comparison of visit-wise mean changes in the CGI-S score between elderly patients (age ≥65, n = 101) and those patients in the study aged <65 (n = 1178) revealed a somewhat more rapid onset of efficacy in younger patients; however, at subsequent visits, the differences between age groups became progressively smaller, and mean changes were essentially equal at endpoint (Eli Lilly and Co 2004).

Study 10 (see Table 4) was a relapse-prevention study in which all patients received open-label duloxetine (60 mg qd) during an initial 12-week acute phase. Acute-phase treatment responders were randomized to treatment with either placebo or duloxetine 60 mg qd for 26 weeks (continuation phase). Duloxetine treatment significantly delayed relapse.

Study 11 (Table 4) was a switching study. Patients exhibiting suboptimal response or poor tolerability to their current antidepressant medication, ie, citalopram (≤40 mg/d), escitalopram (≤20 mg/d), fluvoxamine (≤150 mg/d), paroxetine (≤40 mg/d), sertraline (≤150 mg/d), or venlafaxine (≤150 mg/d) switched directly to duloxetine (60 mg qd) without intermediate tapering or titration (“switching group”). The other half of the patients initiated treatment with duloxetine at either 30 mg qd or 60 mg qd. Duloxetine therapy at 60 mg qd showed significantly greater improvement after 1 week of therapy when compared with those initiating therapy at 30 mg QD. After switching, duloxetine could be titrated up to 120 mg qd. At the end of the study (12 weeks), the efficacy was similar for all groups. Using an SSRI or venlafaxine for at least 1 week reduced the number of adverse events experienced by patients who switched to duloxetine compared with the adverse event profile experienced by patients who began therapy with duloxetine.

Pooled MDD efficacy results and subset analyses
MDD efficacy in males and females
Data pooled from 7 acute trials performed in the US showed that duloxetine was more effective than placebo in both males and females for change in HAMD17, remission, response, and quality of life (Kornstein et al 2006). There was no statistically significant interaction by gender, indicating that duloxetine efficacy is similar for both males and females.

MDD efficacy in Hispanic and African-American patients
The efficacy of duloxetine did not differ between subsets of African-American and Caucasian patients who participated in seven double-blind, placebo-controlled studies (Bailey et al 2006). The efficacy of duloxetine in the African-American patients (as assessed using HAM-D17, CGI-S, and PGI-I scales) did not differ significantly from the efficacy observed in the Caucasian patients who participated in the seven studies.

Efficacy in the treatment of anxious symptoms of depression
Most patients with MDD have anxious symptoms associated with their depression. Effective relief of anxious symptoms is an important factor in the successful treatment of depression.

Dunner et al (2003) reported the efficacy of duloxetine in treating depression-associated anxious symptoms in Studies
<table>
<thead>
<tr>
<th>Study</th>
<th>Purpose</th>
<th>Study design</th>
<th>Treatment (n), acute phase</th>
<th>Treatment duration, acute phase</th>
<th>Response rate (acute phase)</th>
<th>Remission rate (acute phase)</th>
<th>Treatments (n), Continuation phase</th>
<th>Treatment duration, continuation phase</th>
<th>Primary efficacy outcome (continuation phase)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>1-year Safety</td>
<td>Phase III, open label</td>
<td>Duloxetine 40 mg bid</td>
<td>52 weeks</td>
<td>Duloxetine: 68%</td>
<td>Duloxetine: 53%</td>
<td>Duloxetine 60 mg qd (136)</td>
<td>26 weeks</td>
<td>Patients receiving duloxetine 60 mg qd exhibited significantly longer time to relapse compared with placebo log-rank test, ( p = 0.004 )</td>
</tr>
<tr>
<td>10</td>
<td>Relapse Prevention</td>
<td>Phase III, open-label, fixed-dose acute phase followed by randomized, double-blind, placebo-controlled continuation phase</td>
<td>Duloxetine 60 mg qd (533)</td>
<td>12 weeks</td>
<td>Duloxetine 60 mg qd start: 82%</td>
<td>Duloxetine: 60 mg qd start: 80%</td>
<td>Duloxetine 60 mg qd start: 67%</td>
<td>12 weeks</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Switching Study</td>
<td>Phase IIIb, open-label, flexible dosing, acute phase study</td>
<td>Duloxetine 30 mg qd (67) for 1 week, then 60 mg at week 2</td>
<td>26 weeks</td>
<td>Duloxetine 60 mg qd from start (70)</td>
<td>Duloxetine 60 mg qd start: 80%</td>
<td>Duloxetine 60 mg qd start: 67%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4 Summary of other major depressive disorder studies
1, 4, 7, and 8 using the HAM-D, anxiety/somatization subscale, HAM-D Item 10 (anxiety–psychological) and the Hamilton Anxiety Rating Scale (HAMA). Duloxetine was significantly more effective than placebo at relieving anxious symptoms.

In addition, in Study 5, duloxetine (80 mg/day or 120 mg/day) significantly improved both the HAM-D anxiety/somatization subscale and HAMA scale more than placebo (Detke et al 2004).

**Efficacy in patients with melancholic features**

A pooled efficacy analysis of data from Studies 1–8, demonstrated that the advantage of duloxetine over placebo treatment did not differ significantly between melancholic (n = 1278) and non-melancholic patients (n = 635) (Mallinckrodt et al 2005). Furthermore, duloxetine was significantly superior to placebo in both melancholic and non-melancholic cohorts (p ≤ 0.001) for mean change in HAM-D, total score, CGI-S, and PGI-I scales.

**Efficacy in the treatment of painful physical symptoms associated with depression**

Visual analogue scales assessing the severity of overall pain, headache, back pain, and shoulder pain, and interference with daily activities, and amount of time while awake were assessed in many of the clinical trials. Studies 4, 7, and 8 each showed that some painful symptoms improved with duloxetine at 60 mg or 80 mg/d (Goldstein et al 2004a). In Studies 7 and 8, duloxetine consistently reduced bodily pain severity, as measured by visual analog scales (VAS) assessing severity of overall pain, severity of headaches, severity of back pain, severity of shoulder pain, interference with daily activities, and amount of time in pain while awake (Detke et al 2002a, b). Results from the analysis of pooled data (Brannan et al 2005; Fava et al 2004) showed that duloxetine reduced pain severity by 22%–41% (depending on the item) compared with 5%–18% reduction for placebo treatment.

**Safety and tolerability**

Duloxetine was evaluated in 2418 patients with MDD representing 1099 patient-years of exposure including 993 patients treated for at least 180 days and 445 exposed for at least 1 year. Among these 2418 patients, 1139 were enrolled in Studies 1–8 and 1279 patients were enrolled in Studies 9–11. Safety was assessed by adverse events, physical examinations, vital signs, weight, laboratory analyses, and ECGs.

**Tolerability profile in MDD**

In the placebo-controlled database, the incidence of serious adverse events for duloxetine-treated patients (0.3%, 3/1139) was one-half the rate of placebo-treated patients (0.6%, 5/777). In the placebo-controlled database, the incidence of adverse events reported as the reason for discontinuation was significantly greater for patients receiving duloxetine compared with placebo (9.7% vs 4.2%, respectively; p < 0.001 (Tran et al 2003). Nausea was the most common adverse event resulting in discontinuation of duloxetine therapy (1.4% vs 0.1% respectively (Greist et al 2004). The median time to onset of nausea among duloxetine-treated patients was 1 day, while the median duration was 7 days (Greist et al 2004). After the first week of therapy, the incidence of new cases of nausea was essentially equal to placebo. Other adverse events resulting in discontinuation in ≥0.5% of duloxetine-treated patients were somnolence, dizziness, fatigue, and insomnia. In Study 9, the rate of discontinuation due to adverse events was 17.0% in the 1-year trial at 80–120 mg/day (Raskin et al 2003).

**Adverse event profile**

The stated frequencies of adverse events (AEs) represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it first occurred or worsened after receiving study drug therapy without respect to causation.

**Treatment-emergent adverse events**

The incidences of treatment-emergent AEs that occurred in at least 2% of patients treated with Duloxetine, and at a rate greater than placebo, are listed in Table 5 (Eli Lilly and Co 2004). These AEs occurred in patients with MDD treated with duloxetine in a dose range of 40–120 mg/d. The most commonly observed adverse events in duloxetine-treated MDD patients (incidence of 5% or greater and at least twice the incidence in placebo patients) were nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating.

Headache was commonly reported, but was more frequently reported by placebo-treated patients (16.9%) than by duloxetine-treated patients (15.0%). Of the patients that reported nausea with duloxetine, most (94%) reported it as mild or moderate in intensity (Greist et al 2004).
Discontinuation-emergent events
Following abrupt discontinuation, in MDD placebo-controlled clinical trials of up to 9 weeks’ duration, the following symptoms occurred at a rate greater than or equal to 2% and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmare (Eli Lilly and Co 2004). A gradual reduction in dose rather than abrupt cessation is recommended.

Effects on male and female sexual function
Because changes in sexual desire, performance, and satisfaction are manifestations of MDD, but can occur with use of many antidepressants, these were evaluated by both adverse events and the Arizona Sexual Experience Scale (ASEX) (McGahuey et al 2000) in Studies 3, 4, 5, and 6 (Delgado et al 2005). Based on adverse events, duloxetine-treated males had more frequent complaints of abnormal orgasm, ejaculatory dysfunction, decreased libido, erectile dysfunction, and delayed ejaculation and duloxetine-treated females reported more abnormal orgasm and decreased libido. Based on the ASEX, duloxetine-treated males had more difficulty reaching orgasm (ASEX Item 4). Duloxetine-treated females did not experience more sexual dysfunction on duloxetine than on placebo. Paroxetine-treated patients had statistically significantly more sexual dysfunction than duloxetine-treated patients (p = 0.015).

Elderly
Clinical studies of duloxetine did not suggest a difference in adverse event rates in people over or under 65 years of age (Eli Lilly and Co 2004).

Changes in vital signs and ECGs
Cardiovascular effects
Blood pressure and heart rate: Duloxetine treatment, for up to 9 weeks in MDD placebo-controlled clinical trials of 40–120 mg/d doses, caused mean increases in blood pressure, averaging 2 mmHg systolic and 0.5 mmHg diastolic and an increase in the incidence of at least one measurement of systolic blood pressure over 140 mmHg compared with placebo.
Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment (Thase et al 2005).

In the placebo-controlled database, the mean change in heart rate for duloxetine-treated patients was 1.4 beats per minute, while mean changes in systolic and diastolic blood pressure were 0.8 mmHg and 0.9 mmHg, respectively (Thase et al 2005). At the highest duloxetine dose of 120 mg/d, mean increases in systolic and diastolic blood pressure were less than 2 mmHg.

In the placebo-controlled database, there was no significant difference in the incidence of sustained elevation in blood pressure (sustained increases of either systolic or diastolic pressures) between patients receiving duloxetine (1.3%, 14/1116) or placebo (0.8%, 6/757) (Thase et al 2005).

Electrocardiogram changes: Electrocardiograms were obtained from 321 duloxetine-treated patients with major depressive disorder and 169 placebo-treated patients in clinical trials lasting up to 8 weeks. In the placebo-controlled database, mean changes in corrected QT intervals did not differ significantly between duloxetine- and placebo-treated patients (Thase et al 2005). Duloxetine-treated patients actually had small decreases in most assessments, including those patients receiving doses of 120 mg/d. In addition, the incidence of abnormal ECGs (centrally read and/or investigator rated), and the incidence of corrected QT intervals increased >30 msec were essentially identical for duloxetine- and placebo-treated patients. Thus, duloxetine therapy has not been associated with QTc prolongation.

Duloxetine was not associated with the development of clinically significant ECG abnormalities. No clinically significant differences were observed for QT, PR, and QRS intervals between duloxetine-treated and placebo-treated patients.

Weight changes

Many antidepressants are associated with weight gain that can lead to dissatisfaction with treatment and premature discontinuation of therapy. In MDD placebo-controlled clinical trials, patients treated with duloxetine for up to 9 weeks experienced a mean weight loss of approximately 0.5 kg, compared with a mean weight gain of approximately 0.2 kg in placebo-treated patients. In diabetic peripheral neuropathy pain (DPNP) placebo-controlled clinical trials, patients treated with duloxetine for up to 13 weeks experienced a mean weight loss of approximately 1.1 kg, compared with a mean weight gain of approximately 0.2 kg in placebo-treated patients. In the 12-month open-label study (Study 9) (Eli Lilly and Co 2004) patients had a small weight loss early in treatment, returned to baseline weight in succeeding weeks, and had a mean weight increase of 2.1 kg (by repeated measures analysis) after 52 weeks of treatment.

Laboratory changes

Duloxetine treatment, for up to 13 weeks in placebo-controlled clinical trials, was associated with small mean baseline to endpoint increases in ALT, AST, CPK, and alkaline phosphatase (Eli Lilly and Co 2004). Liver transaminase elevations resulted in discontinuation of 0.4% (31/8454) of duloxetine-treated patients. In these patients, the median time to detection of transaminase elevation was about two months. Elevations of ALT to >3 times the upper limit of normal occurred in 0.9% (8/930) of duloxetine-treated and 0.3% (2/652) of placebo-treated MDD patients. In placebo-controlled studies using a fixed dose design, there was evidence of a dose-response relationship for ALT and AST elevation of >3 times and >5 times the upper limit of normal. Since duloxetine and alcohol may interact to cause liver injury, duloxetine should not be prescribed to patients with substantial alcohol use or evidence of chronic hepatic disease.

Other issues

The duloxetine package label (Anonymous 2006) notes other risks that for the most part are similar to most newer antidepressants. As with all antidepressants patients should be observed closely for clinical worsening and suicidality, especially at the beginning of a course of drug therapy, or at the time of dose changes.

Although not studied for duloxetine, patients receiving a serotonin reuptake inhibitor in combination with a monoamine oxidase inhibitor (MAOI) or even starting an MAOI shortly after discontinuing an SSRI, have reported of serious, sometimes fatal, reactions (eg, hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs) and mental status changes, including extreme agitation leading to delirium and coma. Therefore, because duloxetine inhibits the reuptake of serotonin, duloxetine should not be used in combination with an MAOI, within at least 14 days of discontinuing treatment with an MAOI, and at least 5 days should be allowed after stopping duloxetine before starting an MAOI.

If a major depressive episode is the initial presentation of bipolar disorder, treatment with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode.
Since duloxetine has an increased risk of mydriasis, it should be used cautiously in patients with controlled narrow-angle glaucoma.

Since duloxetine is in a class of drugs known to affect urethral resistance, if symptoms of urinary hesitation develop during treatment with duloxetine, consideration should be given to the possibility that they might be drug related.

**Patient perspectives**
Depression and antidepressant treatments can impair quality of life (Wells et al 1990; Revicki et al 1998). Measuring a medication’s impact on quality of life can provide evidence of the drug’s broader efficacy. Patient-reported outcomes measured at baseline and end of trial included the Quality of Life in Depression Scale (QLDS) (McKenna 1992), Sheehan Disability Scale (SDS) (Sheehan et al 1996), and Patient Global Impressions – Improvement (PGI-I).

**Quality of life**
Four of the placebo-controlled trials (5–8) assessed quality of life with the QLDS. Duloxetine produced significantly superior improvement in mean QLDS score, compared with placebo, in both studies of duloxetine 60 mg qd (Studies 7 and 8) (Detke et al 2000a, b) and at an 80 mg/d dose in Study 6. These findings support duloxetine’s efficacy for improving quality of life among patients treated for depression.

The SDS was administered in two of the placebo-controlled studies (Studies 5 and 6). In the acute phase of both studies, patients treated with duloxetine (80 mg/d or 120 mg/d) or paroxetine demonstrated significantly greater improvement on SDS work item, social life item, family life item, and SDS total score compared with placebo-treated patients (Detke et al 2004; Goldstein et al 2004b).

**Somatic symptoms and pain**
As noted above, duloxetine has been shown to reduce physical symptoms associated with depression, particularly painful symptoms. As evidence of its independent effect in painful conditions, duloxetine has demonstrated efficacy in both diabetic peripheral neuropathy pain (Goldstein et al 2005; Raskin et al 2005) and fibromyalgia (Arnold et al 2004, 2005). Therefore, treating both the emotional and the painful physical symptoms of major depression with duloxetine is associated with improvement in patients’ self-reported quality of life. Patients treated with duloxetine also demonstrated consistent improvement across trials on the PGI-I in comparison to placebo.

Finally, since duloxetine is an effective antidepressant and is also effective for DPNP, it may be that it might be particularly useful in patients with both DPNP and depression; however, this combined use has not been studied.

**Dosing and administration**
Taking into account the fact that once-daily dosing is advantageous, especially with regard to ease of use and compliance, duloxetine 60 mg once daily represents the lowest dose with consistent and robust efficacy. Although 60 mg bid demonstrated some numerical advantages over 60 mg qd, the higher dose did not show a significant increase in efficacy but tended to have more frequent adverse events and discontinuations. As a consequence, 60 mg is the appropriate initial dose for most patients.

**Conclusion**
Duloxetine demonstrated antidepressant efficacy at a dose of 60 mg qd in two placebo-controlled, randomized, double-blind studies. Duloxetine-treated patients had significant improvement in reducing the symptoms of depression as assessed by the HAM-D17, anxious symptoms as measured by the HAM-A, and quality of life measures compared with placebo. Duloxetine also improved somatic symptoms, particularly painful symptoms which may have contributed to significantly improved remission rates compared with placebo.

Approximately 10% of the 1139 patients with MDD in placebo-controlled trials discontinued treatment due to an adverse event, compared with 4% of the 777 patients receiving placebo. In addition to nausea (1.4% incidence), which was the most common reason for discontinuation, dizziness, somnolence, and fatigue were the most common AEs reported as reasons for discontinuation and all were considered drug-related.

The most common AEs experienced by and more commonly reported by duloxetine than by placebo-treated patients with MDD were nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating. Duloxetine treatment lacks effects on ECG, increases heart rate, and has little effect on blood pressure or weight.

**Disclosures**
Dr. Goldstein was employed by Eli Lilly and Co, the manufacturer of duloxetine, until 2003 and owns stock in the company. His wife is employed by Eli Lilly and Co.

**References**


